Investors

Introduction

At Alcobra, we remain deeply committed to developing safe and effective products for the treatment of cognitive disorders including ADHD and Fragile X Syndrome and continuing to deliver value for our stockholders.

Our Investor Relations section is designed to provide you with easy access to company information.

NASDAQ: ADHD

$ 1.34

11:44 AM | Feb 28, 2017
-$0.04
(2.90%)

Day High: 1.37
Day Low:  1.30
Volume:    268,201
Delayed ~20 min., by eSignal.